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Abstract
The neurodegenerative disorders are typically characterized by the gradual loss
of neuronal function and structure, also known as neurodegeneration. They are
debilitating conditions that originate from toxic, aggregation–prone proteins. In
particular, Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder, estimated to impact 10 percent of Americans aged 65 years and older,
equating to roughly 5.1 million patients. The disease is defined by the buildup
and presence of two abnormal structures: Extracellular β–amyloid (Aβ) plaques
and interneuronal neurofibrillary tangles. Alzheimer’s disease (AD) is
incurable, whereby current and experimental therapeutic strategies focus
largely upon symptomatic treatment. The role of protein aggregation in
Alzheimer’s disease (AD) therefore mandates the analysis of the ubiquitin–
proteasome system (UPS), specifically in the development and drug–targeting
aspects of neurodegenerative disease. This systematic review draws upon the
existing anti–amyloid and anti–tau therapeutic approaches to propose drug–
targeting upon Ub–protein ligase [E3] and, more generally, the ubiquitin–
proteasome system (UPS) itself to control the accumulation of ubiquitylated
protein substrates.
Keywords: Alzheimer’s disease (AD), β–amyloid (Aβ), neurodegenerative
disease, Ub–protein ligase [E3], ubiquitin–proteasome system (UPS)
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Introduction
Protein Aggregation and Neurodegenerative Disease
The neurodegenerative disorders are typically characterized by the gradual loss of
neuronal function and structure, also known as neurodegeneration. They are debilitating
conditions, wherein the degeneration of nervous system cells (known as “neurons”) prompt their
abnormal function and demise. Their deterioration ultimately causes many symptoms, ranging
from ataxias to dementias.
The neurodegenerative disorders include Alzheimer’s disease, frontotemporal dementia,
Huntington’s disease, Lewy body disease, and Parkinson’s disease, among several others (Table
1). The diverse grouping is known to share the common attribute of neuronal damage caused by
toxic, aggregation–prone proteins. The mutations in the affected genes therefore cause the
“abnormal processing and accumulation of misfiled protein in neuronal inclusions and plaques”
[1].
The neurodegenerative disorders progress with virtually identical pathways, thereby
indicating the possibility for parallel therapeutic options—based heavily upon an “understanding
of the normal cellular mechanisms for disposing of unwanted and potentially noxious proteins”
[1].
An incorrect protein conformation or folding is a “major threat to cell function and
viability, [whereby] elaborate systems have evolved to protect cells from the deleterious effects
of misfolded proteins” [1]. The first safeguard is the molecular chaperone, which attaches itself
to the misfolded polypeptide to correct its folding and inhibit harmful interactions. However, the
molecular chaperone is unable to precisely target each misfolded protein, thereby requiring the
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actions of the ubiquitin–proteasome system (UPS) to eliminate the substantial burden of
defective polypeptide [1].
Table I. Features of Neurodegenerative Diseases (Adapted from Taylor et al. 2002)
Disease
Alzheimer’s Disease
Familial Amytrophic Lateral
Sclerosis (FALS)
Parkinson’s Disease
Polyglutamine Disease

Protein Deposits
Extracellular Plaques;
Intracellular Tangles
Bunina Bodies
Lewy Bodies

Prion Disease

Nuclear and Cytoplasmic
Inclusions
Prion Plaque

Tauopathy

Cytoplasmic Tangles

Toxic Protein
β–amyloid
Superoxide Dismutase 1
(SOD1)
α–Synuclein
Polyglutamine–containing
proteins
Scrapie–associated prion
protein (PrPSc)
Tau

That being said, the neurodegenerative diseases are typically related to protein
aggregation, which directly results from lack of degradation by the ubiquitin–proteasome system
(UPS). It is therefore critical to analyze the role of the ubiquitin–proteasome system (UPS) in the
development and drug–targeting aspects of neurodegenerative disease, given its notable role in
protein degradation (or lack thereof, in neurodegenerative cases).

Ubiquitin–Proteasome System (UPS)
Ubiquitin is a single–chain polypeptide that exists in eukaryotic cells. It primarily serves
to be a regulatory protein that acts to degrade faulty proteins and synthesize other proteins. It
also plays a critical role in other processes, including “novel signaling roles in deoxyribonucleic
acid (DNA) repair and the activation of protein kinases such as IkappaB kinase” [2].
Its role as the “mark of death” requires polyubiquitination, meaning that the degradation–
labeled protein must be tagged by four or more multimers of ubiquitin, which leads to its
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recognition by the 26S proteasome (Figure 1). The 26S proteasome is a large, multicatalytic
complex that degrades polyubiquitinated proteins to small peptides, thus functioning as the waste
disposer of the cell with two 19S caps and 20S catalytic core.
There are three enzymes required to prompt ubiquitination—namely Ub–activating
enzyme [E1], Ub–conjugating enzyme [E2], and Ub–protein ligase [E3]. While the Ub–
activating enzyme [E1] and Ub–conjugating enzyme [E2] play a critical role in preparing
ubiquitin for conjugation, the key enzyme is Ub–protein ligase [E3] due to its role in recognizing
its target protein via protein–binding domain to catalyze the attachment of activated ubiquitin.
The process above is termed the ubiquitin–proteasome system (UPS). The dysfunction of
the ubiquitin–proteasome system (UPS) yields many human diseases—particularly
neurodegenerative disorders, largely “based upon the presence of deposits consisting of
ubiquitylated proteins in affected neurons” [3]. Furthermore, it has been theorized that
“aggregation–prone proteins associated with [neurodegenerative] disorders, such as α–synuclein,
β–amyloid peptide, and polyglutamine proteins, compromise ubiquitin–proteasome system
[UPS] function, and delay the degradation of other proteasome substrates” [3].

Alzheimer’s Disease
Alzheimer’s disease is the most common type of dementia and is estimated to impact 10
percent of Americans aged 65 years and older (roughly 5.1 million individuals). The number of
Americans with Alzheimer’s disease is projected to grow rapidly by 2050 due to the aging “Baby
Boomer” population.
Alzheimer’s disease is a progressive neurodegenerative disorder, typically characterized
by three groups of symptoms: Phase I (Cognitive Dysfunction), which includes executive
dysfunction and memory loss; Phase II (Non–Cognitive Symptoms), which includes behavioral
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disturbances and psychiatric symptoms; and Phase III (Daily Living), which includes the
inability to perform daily activities like dressing and shopping (Figure 2) [4].
The symptoms of Alzheimer’s disease progress from mild to severe dementia and
memory loss. The diagnostic evolution of Alzheimer’s disease has progressed greatly, from its
mid– to late–term diagnosis and management in primary care facilities to early–term diagnosis
and investigation with pharmacological symptomatic treatments and psychosocial support [4].
Alzheimer’s disease is defined by the buildup and presence of two abnormal structures—
namely “extracellular amyloid plaques and intraneuronal neurofibrillary tangles, both of which
comprise highly–insoluble, densely–packed filaments” [5]. The respective structures are
composed of amyloid–β (Aβ) peptides for amyloid plaques and tau for neurofibrillary tangles
(Table 1). The non–cognitive symptoms of Alzheimer’s disease are related to the agglomeration
of plaques and tangles, thereby serving as the “direct consequence of the damage and destruction
of synapses that mediate memory and cognition” [5]. The ubiquitin–proteasome system (UPS) is
associated with early– and late–stages of Alzheimer’s disease, thereby characterized by synaptic
dysfunction and neurodegeneration, respectively.
The ubiquitin–proteasome system (UPS) is known to play a key role in the regular
functioning of synapses. The synaptic dysfunction of early Alzheimer’s disease is thus caused by
defective proteolysis, which is directly impacted by the ubiquitin–proteasome system (UPS).
Moreover, the accumulation of insoluble protein in Alzheimer’s patients may be caused by
“overload or dysfunction of the ubiquitin–proteasome system (UPS), or by conformational
alterations in the protein substrates that prevent their degradation and recognition by the
ubiquitin–proteasome system (UPS)” [6].
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Furthermore, Sudarshan C. Upadhya and Ashok N. Hegde observed that Alzheimer’s
disease and other chronic neurodegenerative diseases are typically accompanied by inclusion
bodies within nerve cells, in conjunction with the abnormal deposition of highly–insoluble
protein aggregates. The inclusion bodies depict “ubiquitin immunoreactivity in Alzheimer’s
disease brains” [7]. However, a more direct relationship between the ubiquitin–proteasome
system (UPS) and pathogenesis of Alzheimer’s disease has also been established, wherein
Alzheimer’s disease is characterized by a frameshift mutation in the ubiquitin transcript with
twenty additional amino acid residues at its C–terminus, called UBB+1.
UBB+1 is present in Alzheimer’s patients. While UBB+1 may serve as the substrate for
polyubiquitination (and, in turn, degradation), its polyubiquitin chains cannot be disassembled by
deubiquitinating enzymes (DUBs) [7], thus inhibiting the 26S proteasomal unit. The research
upon UBB+1 and deubiquitinating enzymes (DUBs) is ongoing, although the inhibitory activity
of UBB+1 is a critical determinant of neurotoxicity that likely yields a favorable environment for
protein aggregates.

Current Therapeutic Strategies
Alzheimer’s disease does not have any functional treatment for suppressing its onset and
progression. In previous years, Alzheimer’s therapeutic research focused upon the
amyloidogenic hypothesis, which hypothesizes that the “β–amyloid (Aβ) peptide is chiefly
responsible for cognitive impairment and neuronal death” [8]. The amyloidogenic–based
treatments have only been modestly effective, wherein their focus lies upon “reduc[ing] β–
amyloid (Aβ) production through the inhibition of β and 𝛾 secretase enzymes and promot[ing]
dissolution of existing cerebral β–amyloid (Aβ) plaques” [8].
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However, the primary obstacle in Alzheimer’s research is the sparse insight related to its
pathogenesis and pathophysiology. For instance, Alzheimer’s disease is known to be
multifactorial, with implicated mechanisms including “tangle formation and spread, dysregulated
protein degradation pathways, neuroinflammation, and loss of support by neurotrophic factors”
[9]. In recent years, Alzheimer’s drug development has therefore shifted from amyloid–centric
approaches to multi–target approaches.

FDA–Approved Medications
The drug–targeting of Alzheimer’s disease is primarily based upon the known features of
its pathological cascade: The first step is the accumulation of β–amyloid (Aβ), followed by the
development of neurofibrillary tangles and neuronal degeneration. The molecular mechanism of
β–amyloid (Aβ) in Alzheimer’s pathogenesis is presently unknown. However, Alzheimer’s
research has depicted the “presence of crosstalk [among] Aβ/Tau in term of molecular signaling
pathways” [10].
In July 2021, the U.S. Food & Drug Administration (FDA) had approved only five drugs
for Alzheimer’s treatment, which fall into two categories: Acetylcholinesterase inhibitors
(AchEIs) and N–methyl–D–aspartate (NMDA) receptor antagonists (Table II). The drugs
provide “symptomatic relief, temporarily improving cognitive function, but are unable to slow
the long–term progression of the disorder through a partial amelioration of cholinergic and
glutamatergic neurotransmission” [10]. The symptomatic treatment has notable drawbacks and
limitations due to the circulatory instability of acetylcholinesterase inhibitors (AchEIs), which
directly correlates with an “unpredictable uptake and bioavailability that may cause
gastrointestinal complications” [10].
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Table II. FDA–Approved Medications (Adapted from Nguyen et al. 2021)
Generic Name

Brand Name

Stage of
Alzheimer’s
Disease

Principal Target

Side Effects

Donepezil

Aricept

All

Selective
Acetylcholinesterase
Inhibitor

Increased
Frequency of
Bowel
Movements;
Loss of Appetite;
Nausea;
Vomiting

Galantamine

Razadyne

Mild to
Moderate

Acetylcholinesterase
and
Butyrylcholinesterase
Inhibitor

Confusion;
Constipation;
Dizziness;
Headache

Memantine

Namenda

Moderate to
Severe

N–methyl–D–
aspartate (NMDA)
Receptor Antagonist

Increased
Frequency of
Bowel
Movements;
Loss of Appetite;
Muscle Cramps;
Nausea;
Vomiting

Rivastigmine

Exelon

Mild to
Moderate

Acetylcholinesterase
and
Butyrylcholinesterase
Inhibitor

Increased
Frequency of
Bowel
Movements;
Loss of Appetite;
Nausea;
Vomiting

Memantine &
Donepezil

Namzaric

Moderate to
Severe

Combined Action

Confusion;
Constipation;
Dizziness;
Headache;
Increased
Frequency of
Bowel
Movements;
Loss of Appetite;
Nausea;
Vomiting
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Experimental Therapeutic Strategies
Anti–Amyloid Approaches
The anti–amyloid therapy is based heavily upon the amyloidogenic hypothesis, which
identifies β–amyloid (Aβ) plaques as the “pathological trigger for a cascade that includes neuritic
injury, formation of neurofibrillary tangles via tau protein, and cell death” [10]. The recent
therapeutic studies have supported the usage of β–amyloid (Aβ) targeting in the novel treatments
for Alzheimer’s disease and cerebral amyloid angiopathy (CAA), referring to the
“cerebrovascular disease directly implicated in Alzheimer’s disease pathogenesis through
amyloid–β (Aβ) deposition, which may cause the development and progression of dementia”
[11].
The pivotal role of β–amyloid (Aβ) highlights the necessity of broadened strategies to
directly or indirectly attack the plaque buildups and deposits thereof. The current
amyloidogenic–based approaches include the following: Antifibrillization Agents; β–Secretase
Inhibitors; γ–Secretase Inhibitors; γ–Secretase Modulators; Statins (Inhibitors of Cholesterol
Biosynthesis); and Vaccination and Immunization Therapies (Figure 3; Table III) [12].

Monoclonal Antibody Treatment
The amyloidogenic hypothesis recently gained notable traction due to the generation of
Aducanumab (or Aduhelm), a “human monoclonal antibody that selectively targets aggregated
β–amyloid (Aβ)” [13]. The monoclonal antibody’s clinical results have justified its development
and usage in Alzheimer’s treatment, given its therapeutic successes in the “transgenic mouse
model of Alzheimer’s disease, [where] Aducanumab is shown to enter the brain, bind
parenchymal β–amyloid, and reduce soluble and insoluble β–amyloid (Aβ) in a dose–dependent
manner” [13].
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Aduhelm’s Phase 3 clinical trials in mild– to moderate–level Alzheimer’s patients have
revealed the following: “1–year of monthly intravenous infusions of [Aduhelm] reduces brain β–
amyloid (Aβ) in a dose– and time–dependent manner, [which] is accompanied by a slowing of
clinical decline measured by Clinical Dementia Ratings (CDR)—Sum of Boxes and Mini Mental
State Examination (MMSE) scores” [13].
The amyloidogenic–directed antibody was approved by the U.S. Food & Drug
Administration (FDA) in June 2021. However, the Food & Drug Administration (FDA) was
confronted with backlash for its approval of Aduhelm under the accelerated approval pathway.
The agency therefore limited the approved patient populace to solely include the following
symptoms to better conform with Biogen clinical trials: Mild cognitive impairment (MCI) or
mild dementia. Despite its controversies and limitations, Aduhelm is regarded as landmark
therapy, whereby the “first–in–class drug will open the door to more efficacious therapies” [14].

Anti–Tau Approaches
The anti–tau therapy is based heavily upon the formation of neurofibrillary tangles and
Tau phosphorylation to Alzheimer’s pathology [10]. After the many failures of β–amyloid (Aβ)
drug–targeting, the clinical studies have “enforced to discover treating tauopathy for
[Alzheimer’s] therapy, targeting prevention of Tau aggregation and improvement of Tau
degradation such as methylene blue, curcumin derivatives, N744, rhodanines, and
aminothienopyridazines (ATPZs)” [10].
The current tauopathy–based approaches include the following: Caspase Inhibitors;
Cholinesterase Inhibitors; Neuroprotective and Neurorestorative Approaches; and Nicotine
Acetylcholine (nAChR) Receptor Agonists (Figure 3; Table III) [12].
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Table III. Abridged Agents or Drugs in Phase 3 of Alzheimer’s Therapeutic Development
(Adapted from Cummings et al. 2021)
Agent

Mechanism Class

Aducanumab*

Amyloid

AGB101 (Low–Dose
Levetiracetam)

Synaptic Plasticity;
Neuroprotection

Atuzaginstat
(COR388)

Inflammation;
Infection

Azeliragon

Amyloid;
Inflammation

Gantenerumab

Amyloid

Solanezumab

Amyloid

TRx0237

Tau

Mechanism of
Action
Monoclonal Antibody
for Aβ Plaques and
Oligomers
SV2A Modulation;
Reduction of Aβ–
Induced Neuronal
Hyperactivity
Bacterial Protease
Inhibitor for
Gingipain by P.
gingivalis; Reduction
of Neuroinflammation
and Hippocampal
Degradation
RAGE Antagonist;
Reduction of Aβ
Transport into Brain;
Mitigation of Toxic
Effects of Oligomers;
Reduction of
Inflammation
Monoclonal Antibody
for Aβ Plaques and
Oligomers
Monoclonal Antibody
for Aβ Monomers
Tau Protein
Aggregation Inhibitor

Therapeutic Purpose
Disease–Modifying
Therapy (DMT)
Disease–Modifying
Therapy (DMT)

Disease–Modifying
Therapy (DMT)

Disease–Modifying
Therapy (DMT)

Disease–Modifying
Therapy (DMT)
Disease–Modifying
Therapy (DMT)
Disease–Modifying
Therapy (DMT)

*See the “Monoclonal Antibody Treatment” sub–section above for more information.

Implications for Future Work
Nanocarrier and Nanoparticle Techniques
The disease–modifying therapies (DMTs) have been unsatisfactory thus far, revealing the
necessity for an “optimization of target subjects and monitoring methods” [10]. The difficulty in
Alzheimer’s research is attributed to many factors, including the high selectivity of the blood–
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brain barrier (BBB), the semipermeable border of “endothelial cells that prevents the solutes in
the circulating blood from non–selectively crossing into the extracellular fluid of the central
nervous system (CNS) where neurons reside, preventing agent[s] from the blood entering the
brain” [10]. The drug–delivering techniques must adapt to effectually traverse the blood–brain
barrier (BBB), thereby indicating that strategies like the drug–loaded nanocarrier and surface–
modified nanoparticle must be adopted into Alzheimer’s research.
The future trajectory of Alzheimer’s clinical research is gradually moving toward the
nanoparticle system, whereby the ultimate hope is to “develop efficient disease–modifying
strategies that aim to deliver the nano–based therapeutic drugs to the brain through the blood–
brain barrier [and] reduce β–amyloid production, aggregation, and clearance, as well as tau
phosphorylation and assembly into neurofibrillary tangles” [10]. The potential and promise of
the nano–based drug delivery mechanism is therefore an exciting development for Alzheimer’s
treatment.

Ubiquitin–Proteasome System (UPS)
Furthermore, the Alzheimer’s therapeutic strategies must focus upon the ubiquitin–
proteasome system (UPS) due to its critical role in promoting highly–insoluble protein
aggregation and synaptic dysfunction. The clinical research largely implicates the role of the
ubiquitin–proteasome system (UPS) in Alzheimer’s disease, yet “systematic and thorough
studies are necessary to pinpoint how each component of the ubiquitin–proteasome system
(UPS) could be linked to synaptic dysfunction or neurodegeneration” [7].
The drug–targeting process also necessitates a greater understanding of the role of
proteolysis in Alzheimer’s disease. However, the current and experimental targets range from
deubiquitinating enzymes (DUBs) to proteasome to Ub–conjugating enzymes [E2]. The largest
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focus must continue to be upon Ub–protein ligase [E3] due to its role in deterring substrate
specificity. The allosteric modification of Ub–protein ligase [E3] may yield “an increased or
decreased affinity towards specific substrates, [which] is one way of controlling accumulation of
the ubiquitylated substrate” [7].
The potential of the ubiquitin–proteasome system (UPS) in Alzheimer’s treatment may
be illuminated by the “studies [up]on genetic polymorphisms within UPS components, combined
with functional validation in animal models” [7]. The continued research upon Ub–protein ligase
[E3] and the ubiquitin–proteasome system (UPS) is therefore critical and may benefit from the
incorporation of selective engineering and modification techniques.

Conclusion
To conclude, Alzheimer’s disease is debilitating to 10 percent of Americans aged 65
years and older, most notably due to the lack of functional treatment for suppressing its onset and
progression. The current and experimental therapeutic strategies are largely symptomatic,
thereby unable to inhibit the long–term progression of the progressive neurodegenerative disease.
The promising implementation of Aduhelm has only highlighted the importance of anti–
amyloid and anti–tau approaches to Alzheimer’s therapy. The systematic review therefore
proposes the necessity for greater insight into the ubiquitin–protease system (UPS) as a possible
Alzheimer’s target, whereby Ub–protein ligase [E3] is promising to control the accumulation of
ubiquitylated protein substrates. This is particularly notable in Alzheimer’s therapeutics, given
that protein accumulation is the key factor in the development of neurodegenerative diseases.
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Appendix
Figure 1. Steps of the Ubiquitin–Proteasome System (UPS) in Substrate Degradation [16]
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Figure 2. Physiological Structure in Normal versus Alzheimer’s Disease (AD) Brain [17]
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Figure 3. Mechanisms of Action (MOA) of Agents in Phase 3 Clinical Trials [15]
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